TapImmune CEO Discusses Company’s Clinical Programs in Recent Print and Radio Interviews

In multiple industry-related media Dr Glynn Wilson discusses status of clinical programs and advancement from phase 1 to phase 2 trials

SEATTLE, Nov. 24, 2014 /PRNewswire/ — TapImmune, Inc. (OTCQB: TPIV), is pleased to point its shareholders to the following press articles published recently in which TapImmune CEO Dr Glynn Wilson has been interviewed. In light of the company’s recent news about the establishment of a Phase 2 collaboration and advancement of both clinical programs, the company would like to direct its shareholders to these articles and interviews where Dr Wilson has discussed the progression of clinical trials and TapImmune’s technology approach.

TapImmune is advancing 2 distinct clinical programs from Phase 1 to Phase 2 in Breast and Ovarian Cancer. Interim data from both programs has indicated that the Phase 1 programs have been successful with respect to overall safety and immune responses. These data provide the rational for clinical progression of both programs. The company is preparing these data for end of phase I pre-phase II meetings with FDA as we seek guidance on the fastest way forwards with both programs.

More information can be seen on the company website and in these industry-related articles and interviews.

http://www.examiner.com/article/new-technology-may-speed-up-ebola-vaccine-development 21-11-2014

Money Talk Station Weekly Interview 11-18-2014


ehealth Radio Network 10-10-2014


Life Sciences Intellectual Property Review 10-29-2014


PBG Lifestyle Magazine 10-228-2014


Drug Discovery & Development 9-16-2014


Drug Development & Delivery 9-22-2014


Please visit the company website for additional media coverage https://www.markertherapeutics.com/news-media/

About TapImmune Inc.

TapImmune Inc. is an immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease. The Company’s vaccine compositions, peptide or nucleic acid-based, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients’ killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company’s vaccine compositions may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company’s website at markertherapeutics.com for details.

Safe Harbor Statement

This press release contains certain statements that may include “forward-looking statements.” All statements other than statements of historical fact included herein are “forward-looking statements.” These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including the risk factors discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on the SEC’s website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

Glynn Wilson, PH.D.
Chairman & CEO

Investor Relations
J.Streicher Capital, LLC.
Robert Giordano
Tel: +1-212-257-5495
Cell: +1-917-327-3938
Email: rgiordano@jstreichercapital.com

SOURCE TapImmune Inc.